Diana Chirovsky
YOU?
Author Swipe
View article: Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is)
Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is) Open
INTRODUCTION Advances in targeted therapies have resulted in extended survival for many pts with CLL/SLL. OS is a key endpoint in oncology, but in 1st Line CLL studies, it often takes longer to mature due to the disease's indolent nature; …
View article: Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study Open
ClinicalTrials.gov (https://clinicaltrials.gov/), NCT03829319.
Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden Open
Background: In a previous study, we explored real-world programmed death-ligand 1 (PD-L1) testing and treatment patterns for patients with advanced non-small cell lung cancer (NSCLC) in the era of immune-oncology. The present study aimed t…
View article: Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer Open
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We …
View article: Network meta-analysis of pembrolizumab as monotherapy and in combination with chemotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma
Network meta-analysis of pembrolizumab as monotherapy and in combination with chemotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma Open
Pembrolizumab monotherapy or in combination with chemotherapy is approved as first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on improved overall survival (OS) versus EXTREME regimen in t…
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors Open
Background Front-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is the standard of care for treating patients with advanced nonsquamous NSCLC with the common sensitizing EGFR exon 19 deletion and exon 21 L858R point mutations. H…
112P Treatment landscape for stages I–III NSCLC in the United States (US) community setting before and after 2020 Open
Treatment approaches for stages I–III NSCLC are rapidly evolving due to recent regulatory approvals of EGFR-targeted therapy and immunotherapy, increasing the importance of understanding real-world treatment patterns in US community practi…
Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations Open
Background: The current therapy for advanced non-small-cell lung cancer (NSCLC) often incorporates frontline use of programmed death (ligand) 1 [PD-(L)1] inhibitors concomitantly or sequentially with platinum-based chemotherapy. For patien…
View article: Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer
Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer Open
BACKGROUND: Intermediate endpoints, such as disease-free survival (DFS), have shown good correlation with overall survival (OS) in early-stage non-small cell lung cancer (NSCLC) clinical trials. However, real-world data are limited, and no…
View article: Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection
Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection Open
Aim: Real-world data on outcomes for early-stage non-small-cell lung cancer (NSCLC) are needed to better understand the benefits of new therapies. Methods: In this retrospective study using the ConcertAI Patient360™ database, overall survi…
Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data Open
Despite clinical guideline recommendations, rate of adjuvant chemotherapy among patients with resected early-stage NSCLC was low in clinical practice. Overall, among patients with early-stage NSCLC treated with conventional primary surgery…
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States Open
First-line pembrolizumab monotherapy in patients with CPS ≥1, and pembrolizumab combination therapy in the overall R/M HNSCC population is cost-effective from the perspective of the US payers.
View article: Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis
Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis Open
Background Overall survival (OS) is the most patient-relevant outcome in oncology; however, in early cancers, large sample sizes and extended follow-up durations are needed to detect statistically significant differences in OS between inte…
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048 Open
Pembrolizumab monotherapy and pembrolizumab-chemotherapy extended OS while maintaining HRQoL, further supporting first-line use for R/M HNSCC.
Corrigendum: Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States Open
[This corrects the article DOI: 10.3389/fpubh.2020.624092.].
Real-World Time on Treatment with Immuno-Oncology Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Aim: We report real-world time on treatment (rwToT) with immuno-oncology (I-O) and other systemic therapies in second-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) previously treated with platinum therapies…
Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina Open
Pembrolizumab either as monotherapy or in combination with chemotherapy offers substantial survival gains for patients with R/M HNSCC at small additional costs, making it a cost-effective treatment versus cetuximab + platinum + 5-FU in Arg…
Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States Open
Objectives: To estimate years of potential life lost (YPLL) and present value of future lost productivity (PVFLP) associated with premature mortality due to HPV-attributable cancers, specifically those targeted by nonavalent HPV (9vHPV) va…
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040 Open
Background Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs standard of care (SOC) in…
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study Open
Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments.
Comparative Effectiveness of Surveillance and Current Treatment Approaches for the Detection and Management of Hepatocellular Carcinoma in East Asia Open
Treatment approaches for hepatocellular carcinoma (HCC) in China are distinct in the use of resection with more advanced HCC, and continued research is needed to re-evaluate the appropriateness of guideline recommendations. Surveillance is…
Assessing the Comparability of Paper and Electronic Versions of the EORTC QOL Module for Head and Neck Cancer: A Qualitative Study Open
Mode of administration does not affect participants' response to, or interpretation of, items in the EORTC QLQ-H&N35. The findings from this study add to the existing evidence supporting the use of electronic versions of the EORTC instrume…